{
    "clinical_study": {
        "@rank": "24960", 
        "arm_group": [
            {
                "arm_group_label": "G-CSF + plerixafor", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses."
            }, 
            {
                "arm_group_label": "G-CSF + Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is to determine if NHL patients mobilized with G-CSF (10 \u00b5g/kg/day [GRAN\u00ae only])\n      plus 0.24 mg/kg/day of plerixafor are more likely to achieve a target number of \u22655 \u00d7 10^6\n      CD34+ cells/kg in 4 or fewer days of apheresis than NHL patients mobilized with G-CSF plus\n      placebo."
        }, 
        "brief_title": "Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5\u00d710^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligible patients who are unable to achieve adequate apheresis cell counts may enter an\n      Open-Label Rescue Period where they will receive plerixafor, following the same study\n      schedule as during the Double-Blind Treatment Period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has a biopsy-confirmed diagnosis of NHL\n\n          -  Is in first or second complete remission or partial remission, defined for the\n             purpose of this study as complete or partial response following first- or second-line\n             therapy\n\n          -  Treatment with an autologous peripheral HSC transplant is planned and the patient is\n             eligible for autologous transplantation\n\n          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n\n          -  Has recovered from all acute toxic effects of prior chemotherapy or other cancer\n             treatment.\n\n          -  Has an actual body weight <175% of their ideal body weight (IBW)\n\n          -  The patient agrees to use a highly effective method of contraception from Day 1\n             through \u22653 months following plerixafor treatment.\n\n        Exclusion Criteria:\n\n          -  Concurrent serious illness and pathological conditions\n\n          -  Has undergone previous HSC collections or collection attempt\n\n          -  Has had any autologous or allogeneic HSC transplant\n\n          -  Has active central nervous system (CNS) involvement\n\n          -  Bone marrow lymphoma cells involvement >20%, as assessed by bone marrow biopsy within\n             4 months before signing the ICF\n\n          -  Has received radiation therapy to the pelvis\n\n          -  Has a diagnosis of all leukemias including any type of CLL\n\n          -  Active infection\n\n          -  Pregnant or nursing\n\n          -  Anticipated post-transplant chemotherapy and/or radiation therapy below the diaphragm\n\n          -  Received any prior radio-immunotherapy\n\n          -  Prior 1,3-bis(2-chloroethyl)-1-nitroso-urea (BCNU) within 6 weeks prior to first dose\n             of G-CSF\n\n          -  Prior cancer therapy, other investigational therapy within 4 weeks prior to first\n             dose of G-CSF\n\n          -  Prior granulocyte/macrophage-colony stimulating factor (GM-CSF) or pegfilgrastim\n             within 3 weeks prior to the first dose of G-CSF\n\n          -  Prior G-CSF within 2 weeks prior to the first dose of G-CSF\n\n          -  Inadequate organ funtion evidenced by unacceptable laboratory result"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01767714", 
            "org_study_id": "EFC12482", 
            "secondary_id": [
                "MOZ14409", 
                "U1111-1131-0145"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "G-CSF + plerixafor", 
                    "G-CSF + Placebo"
                ], 
                "description": "10 \u00b5g/kg/day G-CSF, administered by subcutaneous (SC) injection", 
                "intervention_name": "Granulocyte-colony stimulating factor (G-CSF)", 
                "intervention_type": "Drug", 
                "other_name": "GRAN\u00ae, Filgrastim"
            }, 
            {
                "arm_group_label": "G-CSF + plerixafor", 
                "description": "0.24 mg/kg/day subcutaneous injection", 
                "intervention_name": "Plerixafor", 
                "intervention_type": "Drug", 
                "other_name": "Mozobil, AMD3100, GZ316455"
            }, 
            {
                "arm_group_label": "G-CSF + Placebo", 
                "description": "0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Lenograstim", 
                "JM 3100"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "hematopoietic stem cell transplantation", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100071"
                    }, 
                    "name": "Investigational Site Number 156005"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100034"
                    }, 
                    "name": "Investigational Site Number 156017"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100730"
                    }, 
                    "name": "Investigational Site Number 156003"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100142"
                    }, 
                    "name": "Investigational Site Number 156002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100044"
                    }, 
                    "name": "Investigational Site Number 156001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100853"
                    }, 
                    "name": "Investigational Site Number 156004"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "zip": "410008"
                    }, 
                    "name": "Investigational Site Number 156014"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "zip": "400037"
                    }, 
                    "name": "Investigational Site Number 156020"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "zip": "350001"
                    }, 
                    "name": "Investigational Site Number 156016"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510515"
                    }, 
                    "name": "Investigational Site Number 156012"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }, 
                    "name": "Investigational Site Number 156021"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "zip": "310003"
                    }, 
                    "name": "Investigational Site Number 156011"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "zip": "210029"
                    }, 
                    "name": "Investigational Site Number 156018"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200025"
                    }, 
                    "name": "Investigational Site Number 156009"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200433"
                    }, 
                    "name": "Investigational Site Number 156019"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suzhou", 
                        "country": "China", 
                        "zip": "215006"
                    }, 
                    "name": "Investigational Site Number 156010"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "zip": "300020"
                    }, 
                    "name": "Investigational Site Number 156008"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "zip": "430022"
                    }, 
                    "name": "Investigational Site Number 156013"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'An", 
                        "country": "China", 
                        "zip": "710038"
                    }, 
                    "name": "Investigational Site Number 156015"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China", 
                        "zip": "450008"
                    }, 
                    "name": "Investigational Site Number 156022"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of Plerixafor (0.24 mg/kg) Plus G CSF (10 \u00b5g/kg) Versus G CSF (10 \u00b5g/kg) Plus Placebo to Mobilize and Collect \u22655 \u00d7 106 CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation", 
        "overall_contact": {
            "email": "Contact-Us@sanofi.com", 
            "last_name": "For site information, send an email with site number to"
        }, 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients who meet the target of \u22655 \u00d7 10^6 CD34+ cells/kg in 4 or fewer days of apheresis", 
            "safety_issue": "No", 
            "time_frame": "Days 5- Day8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01767714"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients who achieve \u22652 \u00d7 10^6 CD34+ cells/kg within 4 or fewer days of apheresis", 
                "safety_issue": "No", 
                "time_frame": "Day 5 - Day 8"
            }, 
            {
                "measure": "Number of days of apheresis to collect \u22652 \u00d7 10^6 CD34+ cells/kg", 
                "safety_issue": "No", 
                "time_frame": "Up to achieve the target of collecting \u22652 \u00d7 10^6 CD34+ cells/kg"
            }, 
            {
                "measure": "Number of days of apheresis to collect \u22655 \u00d7 10^6 CD34+ cells/kg", 
                "safety_issue": "No", 
                "time_frame": "Up to achieve the target of collecting \u22655 \u00d7 10^6 CD34+ cells/kg"
            }, 
            {
                "measure": "Total number of CD34+ cells collected", 
                "safety_issue": "No", 
                "time_frame": "Day 5 - Day 8"
            }, 
            {
                "measure": "Time from transplantation to neutrophil and platelet (PLT) engraftment", 
                "safety_issue": "No", 
                "time_frame": "up to 30 days post-transplantation"
            }, 
            {
                "measure": "Number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "from signed Informed Consent Form (ICF)  to 30 days post-transplant and then ongoing as needed"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Time to reach Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Area Under the Curve 0 to 10 hours post-dose (AUC0-10)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Area Under the Curve 0 to last observed concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Area Under the Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Percentage of extrapolation of AUC (AUCext)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Half life (T1/2)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Volume of distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Total body clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "Peripheral blood CD34+ cell counts (Pharmacodynamic analysis)", 
                "safety_issue": "No", 
                "time_frame": "Day 4 - Day 5"
            }, 
            {
                "measure": "The fold-increase in the number of circulating CD34+ following the first dose of plerixafor or placebo, with the first apheresis day (Day 5) value serving as the primary estimate", 
                "safety_issue": "No", 
                "time_frame": "Day 5 - Day 8"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}